Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide.

Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...

Roche has entered an exclusive collaboration and licensing agreement with Zealand Pharma under which the parties will ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Neskovic 3-8 2-2 8, Walz 6-10 4-4 16, Artis White 6-10 0-0 17, Roche 0-2 0-0 0, Tyne 3-10 0-0 8, Tanner 3-6 2-3 9, D'Entremont 1-2 0-0 3, Hunt 0-3 0-0 0, Beagle 1-2 2-2 4. Totals 23-53 10-11 65.

Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Donald Trump has criticised Ireland for using its tax policies to lure away US companies, as he threatened to escalate his ...

Osnat Manning (lady President), Adam Farrell (Junior Captain), Mary Robinson (lady Captain), Maurice Delaney (Captain), Georgia Harrington (Junior lady Captain) and Ray Heffernan (President) at the ...

Norman worked as a model starting in the 1970s, working for Essence, Vogue Italia, Harper's Bazaar India, and walking runways ...